Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 25 (Reuters) - Merck (MRK.N), opens new tabsaid on Wednesday it would buy biotech Terns Pharma (TERN.O), opens new tabin a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda. Sign up here. Reporting by ...